to the alveolar compartment. Both focus on the importance of the appropriate animal model Although one would predict that surfactant replacement therapy would be studies. Indeed, it was another five years before Enhorning and Robertson successfully instilled effective in acute respiratory distress syndrome (ARDS), a recent large trial proved mature rabbit surfactant to rescue premature pups. 2 SRT is now used routinely in neonatal unsuccessful, possibly reflecting the nature of the surfactant used. Given the intensive care units where it has reduced the mortality of infants under 29 weeks gestation importance of the unique proteins in the action of surfactant, these would seem vital by as much as 50%.
then resulted in surfactant deficiency. With processing of surfactant which normally leads to the formation of an active monolayer (fig is to use a bronchoscope both to lavage and then to instil surfactant directly into the worst affected regions identified by computed tomographic scanning. This would tend to remove from the alveolus mediators which potentiate lung injury while minimising the dose of surfactant.
  
The pattern of breathing clearly affects surfactant homeostasis and composition. 8 is consistent with surfactant being released by distortion of the type II cell. 8 The rate of reuptake of surfactant is related to the rate of Importantly, some of these changes are apparent in "at risk" patients. 5 We need more release rather than to the amount in the alveolus, and both can be increased by adinformation relating surfactant composition (possibly even including SP-A isoforms) in the renoceptor agonist drugs. 8 Finally, increasing V also increases the rate of synthesis of surindividual patient to the initial insult, the inspired oxygen, and the ventilatory regimen.
factant phospholipids. 8 It may therefore be possible to titrate ventilation in order to minimise the alveolar surfactant required and actually alter its composition 9 while increasing synthesis    Exosurf is a protein-free preparation which and turnover pharmacologically. The damage due to high inspired oxygen and volumes might combines DPPC with tyloxapol and hexadecanol as emulsifiers and spreading agents. be minimised by monitoring serum SP-A and SP-B as indices of alveolocapillary Given the vital role of the surfactant proteins in overcoming the surfactant inactivating prop-permeability.
11 12 erties of plasma proteins in maintaining the surface active, large, tubular myelin-rich aggregates of surfactant which then form the active monolayers, one must conclude that Therapeutic potential
Patients considered "at risk" would be idenExosurf was a poor choice. Indeed, Exosurf is only effective in about 50% of neonates with tified from serum levels of SP-A and SP-B, 12 their surfactant composition determined from RDS, 6 possibly only those with sufficient endogenous surfactant proteins. As patients with tracheal aspirates, and complementary preparations of synthetic phospholipids and sur-ARDS are very susceptible to nosocomial pneumonia, the ideal exogenous surfactant might factant proteins formulated. Patients would then be treated prophylactically by aerosol at contain SP-A for its host defence capabilities, as well as for its ability to stimulate re-uptake a stage when their lungs are still ventilating relatively normally. This would be economical, of alveolar surfactant leading to increased de novo synthesis. Finally, SP-A and SP-B may provide a homogeneous distribution, prevent the vicious cycle, and allow the lung time to reverse the abnormally low ratio of large to small surfactant aggregates found in ARDS. 7 repair. In patients with overt ARDS focal lavage and surfactant instillation via a bronchoscope would be complemented with a low V/high EEP ventilation regimen, possibly incorporat-   In neonatal RDS the surfactant deficiency is ing permissive hypercapnia, 10 thus minimising the need for surfactant while avoiding the risk relatively homogeneous so that a bolus of approximately 100 mg/kg surfactant has a homo-of barotrauma. adrenoceptor agonist drugs might be included in the instillate to increase geneous effect. A disadvantage of this approach in ARDS is the amount required, costing as surfactant turnover, resolve oedema, and increase mucociliary transport. Finally, it is unmuch as $US 70 000 per patient. Whereas nebulisation is more economical, <5% of sur-reasonable to expect SRT to reverse end stage ARDS with widespread destruction of the factant reaches the lungs 4 and is deposited in the better ventilated alveoli where it is least alveolocapillary membrane. Possibly these patients would benefit from liquid ventilation. required. A different approach, albeit invasive, group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from
